PPT-Peginterferon alfa-2a +

RBV versus Interferon alfa 2a RBV ACTG 5071 Phase 2 Treatment Naïve Chronic HCV and HIV Chung RT et al N Engl J Med 20043514519 PEG alfa 2a RBV versus. PRODUCT MONOGRAPH interferon alfa-2b Lyophilized Powder with Diluent10 million IU interferon alfa-2b/vial 18 million IU interferon alfa-2b/vial Ready-to-Use Solution 10 million IU interferon alfa-2b/v Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of the Alfa Laval spiral heat exchangers Problem solvers for tough applications 2 Alfa Laval – spiral heat exchangers severe fouling. When it’s nally time for maintenance SHEs are considerably sa RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Overview. . of. . PECS . projects. European Space . Agency Information . Day. 1. 1. th. January. , 2017. Point of Contact: . Ms. . Maite. Trujillo: maite.trujillo@esa.int. Mr. Laurent . Marchand. with PEG + RBV in Genotype 1. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. Using . SiPM. to readout Scintillating Fibers . What has been done for ALFA. The “Scintillating Fibers & . SiPM. ” status of the art. . ALFA. . SiPM. Collecting Information. Starting discussion. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . Mark Sulkowski, MD. Professor of Medicine. Johns Hopkins University. Baltimore Maryland 21212. Case . 57 . yo. woman with genotype 1a and bridging fibrosis. PROVE-1 study – treated with TVR x 12 . versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin.